Examining the Impact of Trial Length on Detecting Medication Effects for Alcohol Use Disorder: A Meta‐Regression Study
Alcohol, Clinical and Experimental Research · 2026-06 · 50 (6)
DOI: 10.1111/acer.70306 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Alcohol, Clinical and Experimental Research, online erschienen am 12.06.2026. Verfasst von Malia A Belnap und 6 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Interdepartmental Program, University of California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Alcoholism, Randomized Controlled Trials as Topic, Alcohol Deterrents. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAAA NIH HHS, National Institute on Alcohol Abuse and Alcoholism.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Background
The U.S. Food and Drug Administration (FDA) recommends a minimum duration of 6 months for randomized controlled trials (RCTs) evaluating pharmacotherapies for alcohol use disorder (AUD). The relationship between trial length and treatment effects is not well understood. The current study conducted meta‐regression analyses of RCTs for AUD to examine the association between trial length and observed medication effect sizes in clinical trials.
Methods
This secondary data analysis utilized data from a systematic literature review that identified 139 pharmacotherapy RCTs for AUD conducted between 1985 and 2023. Meta‐regressions were conducted using the metafor package in R to examine whether shorter (< 12 weeks) or longer (> 12 weeks) trials differed in observed medication effect sizes for abstinence‐ and drinking‐based endpoints, relative to 12‐week trials, which represented the median trial duration. Publication bias was addressed using a weight‐function model.
Results
For abstinence‐based endpoints, neither shorter (< 12 weeks; β = 0.13, SE = 0.21, p = 0.54) nor longer (> 12 weeks; β = 0.11, SE = 0.11, p = 0.30) trials differed significantly from the 12‐week reference group in observed medication effect sizes. Similarly, for drinking‐based endpoints, neither shorter (< 12 weeks; β = −0.07, SE = 0.09, p = 0.39) nor longer (> 12 weeks; β = 0.06, SE = 0.05, p = 0.26) trials differed significantly from 12‐week trials in observed medication effect sizes. All results remained nonsignificant after adjusting for publication bias. In sensitivity analyses restricted to trials with statistically significant effect sizes, trials > 12 weeks showed smaller estimated treatment effects compared to trials ≤ 12 weeks.
Conclusions
Observed medication effect sizes did not differ significantly across trial lengths for abstinence and drinking‐based endpoints, except for analyses restricted to trials with significant effect sizes, where there was an advantage for trials that were 12 weeks or shorter. These findings inform efforts to optimize AUD RCT design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroscience Interdepartmental Program, University of California, Los Angeles, California, USA.
- Department of Psychology, University of California, Los Angeles, California, USA.
- Center on Alcohol, Substance Use, and Addictions (CASAA), University of New Mexico, Albuquerque, New Mexico, USA.
- Department of Psychology, University of New Mexico, Albuquerque, New Mexico, USA.
- Department of Psychiatry, University of Colorado Anschutz School of Medicine, Aurora, Colorado, USA.
- Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.
ORCID-Profile: Katie Witkiewitz, Joseph P Schacht, Raymond F Anton, Steven J Nieto, Lara A Ray
Förderung
- NIAAA NIH HHS
- National Institute on Alcohol Abuse and Alcoholism
Zitieren
APA
Belnap, M. A., Witkiewitz, K., Schacht, J. P., Anton, R. F., Aldridge, A. P., Nieto, S. J., & Ray, L. A. (2026). Examining the Impact of Trial Length on Detecting Medication Effects for Alcohol Use Disorder: A Meta‐Regression Study. Alcohol, Clinical and Experimental Research, 50(6). https://doi.org/10.1111/acer.70306
Vancouver
Belnap MA, Witkiewitz K, Schacht JP, Anton RF, Aldridge AP, Nieto SJ, et al. Examining the Impact of Trial Length on Detecting Medication Effects for Alcohol Use Disorder: A Meta‐Regression Study. Alcohol, Clinical and Experimental Research. 2026;50(6). doi:10.1111/acer.70306
BibTeX
@article{Belnap2026,
author = {Belnap, Malia A and Witkiewitz, Katie and Schacht, Joseph P and Anton, Raymond F and Aldridge, Arnie P and Nieto, Steven J and Ray, Lara A},
title = {Examining the Impact of Trial Length on Detecting Medication Effects for Alcohol Use Disorder: A Meta‐Regression Study},
journal = {Alcohol, Clinical and Experimental Research},
year = {2026},
volume = {50},
number = {6},
doi = {10.1111/acer.70306}
}
EUVIMED